Logo

Omeros Corporation

OMER

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has comple… read more

Healthcare

Biotechnology

13 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$4.11

Price

+0.12%

$0.01

Market Cap

$279.369m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$412k

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$122.474m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$2.11

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

-$228.685m

$200.569m

Assets

$429.254m

Liabilities

$184.333m

Debt
Debt to Assets

91.9%

-1.5x

Debt to EBITDA
Free Cash Flow

-$118.898m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases